Clinical Trial Update: Study of S-1 as Second Line Treatment on Advanced Pancreatic Cancers [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating S-1 as second-line treatment for advanced pancreatic cancer is underway; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Conditions: Pancreatic Cancer | Phase 2 | Status: UNKNOWN